IL180460A - COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT - Google Patents

COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT

Info

Publication number
IL180460A
IL180460A IL180460A IL18046006A IL180460A IL 180460 A IL180460 A IL 180460A IL 180460 A IL180460 A IL 180460A IL 18046006 A IL18046006 A IL 18046006A IL 180460 A IL180460 A IL 180460A
Authority
IL
Israel
Prior art keywords
cancer
combined preparation
hsp90 antibody
treating cancer
cancer agent
Prior art date
Application number
IL180460A
Other languages
English (en)
Other versions
IL180460A0 (en
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0414885A external-priority patent/GB0414885D0/en
Priority claimed from GB0420845A external-priority patent/GB0420845D0/en
Priority claimed from GB0503566A external-priority patent/GB0503566D0/en
Priority claimed from PCT/GB2005/002545 external-priority patent/WO2006003384A1/en
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Publication of IL180460A0 publication Critical patent/IL180460A0/en
Publication of IL180460A publication Critical patent/IL180460A/en

Links

IL180460A 2004-07-02 2006-12-31 COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT IL180460A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0414885A GB0414885D0 (en) 2004-07-02 2004-07-02 Cancer therapy
GB0420845A GB0420845D0 (en) 2004-09-20 2004-09-20 Treatment of cancer
US61442304P 2004-09-30 2004-09-30
GB0503566A GB0503566D0 (en) 2005-02-21 2005-02-21 Treatment for cancer
US65445805P 2005-02-22 2005-02-22
PCT/GB2005/002545 WO2006003384A1 (en) 2004-07-02 2005-06-30 Treatment of cancer

Publications (2)

Publication Number Publication Date
IL180460A0 IL180460A0 (en) 2007-06-03
IL180460A true IL180460A (en) 2010-12-30

Family

ID=39124615

Family Applications (1)

Application Number Title Priority Date Filing Date
IL180460A IL180460A (en) 2004-07-02 2006-12-31 COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT

Country Status (8)

Country Link
JP (1) JP2008504355A (es)
BR (1) BRPI0512889A (es)
EC (1) ECSP077219A (es)
IL (1) IL180460A (es)
MA (1) MA28701B1 (es)
MX (1) MX2007000263A (es)
NZ (1) NZ552508A (es)
SG (1) SG153877A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
BRPI0512889A (pt) 2008-04-15
SG153877A1 (en) 2009-07-29
ECSP077219A (es) 2007-03-29
JP2008504355A (ja) 2008-02-14
MA28701B1 (fr) 2007-06-01
NZ552508A (en) 2009-10-30
IL180460A0 (en) 2007-06-03
MX2007000263A (es) 2007-07-20

Similar Documents

Publication Publication Date Title
EP1851244A4 (en) ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
EP1718145A4 (en) CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
IL188588A0 (en) Anti-ctla -4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
PL2100618T3 (pl) Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
EP1732650A4 (en) COMPOSITION AND METHOD FOR CANCER TREATMENT
IL210401A0 (en) Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
IL191938A (en) The ovarian heterocellular compounds, pharmaceuticals containing them, and the ovarian heterocellular compounds for cancer treatment
IL177201A0 (en) Methods and compositions for treating tumors and metastatic disease
EP1793858A4 (en) HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
GB0418328D0 (en) Cancer methods and medicaments
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP1844789A4 (en) EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
EP2123266A4 (en) THERAPEUTIC AGENT AGAINST CANCER AND ANTI-CARCINOGENIC AGENT
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP1724271A4 (en) PREVENTIVE AND / OR THERAPEUTIC AGENT AGAINST NEUTROPHIC INFLAMMATORY DISEASE
GB0625100D0 (en) Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
HK1110224A1 (en) Therapeutic agent for cancer
EP1596806A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER USING IGSF9 AND LIV-1
EP1626711A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
GB0413346D0 (en) Treating cancer
IL180460A (en) COMBINED PREPARATION FOR TREATING CANCER COMPRISING AN ANTI-Hsp90 ANTIBODY AND AT LEAST ONE ANTI-CANCER AGENT

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees